“Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma”, J of Skin, vol. 2, p. S79, Dec. 2018, doi: 10.25251/skin.2.supp.79.